Detalhe da pesquisa
1.
Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome.
Ann Neurol
; 93(3): 604-614, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36401339
2.
Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.
J Neurol Neurosurg Psychiatry
; 94(10): 792-799, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37173129
3.
Evaluating the efficacy and safety of transitioning patients with multiple sclerosis from natalizumab to ocrelizumab (OCTAVE).
Mult Scler
; 29(8): 956-966, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37317841
4.
Relapse recovery in relapsing-remitting multiple sclerosis: An analysis of the CombiRx dataset.
Mult Scler
; 29(14): 1776-1785, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37830451
5.
Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis.
Eur J Neurol
; 30(9): 2761-2768, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37306560
6.
MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis.
Mult Scler
; 28(4): 561-572, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34304609
7.
Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS.
Mult Scler
; 28(8): 1286-1298, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34965774
8.
The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.
Mult Scler
; 28(10): 1606-1619, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876467
9.
Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.
Eur J Neurol
; 29(4): 1106-1116, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34927308
10.
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
N Engl J Med
; 379(9): 846-855, 2018 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30157388
11.
Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?
Eur J Neurol
; 28(6): 2115-2120, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33448539
12.
Fast whole-brain three-dimensional macromolecular proton fraction mapping in multiple sclerosis.
Radiology
; 274(1): 210-20, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25208343
13.
The nine hole peg test as an outcome measure in progressive MS trials.
Mult Scler Relat Disord
; 69: 104433, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36462470
14.
Longitudinal Changes in Cognitive Test Scores in Patients With Relapsing-Remitting Multiple Sclerosis: An Analysis of the DECIDE Dataset.
Neurology
; 101(1): e1-e11, 2023 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37072219
15.
Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis.
Front Neurol
; 14: 1188124, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37360346
16.
Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions.
Ann Clin Transl Neurol
; 10(11): 2053-2064, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37675826
17.
Podcast on B Cell-Targeting Therapies and Other Multiple Sclerosis Concerns During COVID-19.
Neurol Ther
; 11(2): 515-524, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35066816
18.
Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions.
Int J MS Care
; 24(4): 184-188, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35875463
19.
Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset.
J Neurol
; 269(3): 1663-1669, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34392376
20.
The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
J Neurol
; 269(10): 5319-5327, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35570237